Anti-RGMA Antibody (Elezanumab)

▌ Introduction

Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets the repulsive guide molecule A (RGMa). Elezanumab effectively inhibits RGMa-mediated BMP signaling through the SMAD1/5/8 pathway, IC50 About 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in models of neuronal injury and demyelination, binds to N-terminal RGMa, blocks BMP signaling, and lacks RGMc cross-reactivity. Elezanumab has neuroregenerative and neuroprotective activity and has no effect on iron metabolism

▌ Product parameters

Alternative Names	ABT-555
Target Accession	Q96B86
Target	RGMA
CAS number	1791416-49-3
Molecular Weight	150 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80℃
Expiration Date	2 years

Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.

APExBIO Technology
www.apexbt.com
7505 Fannin street, Suite 410, Houston, TX 77054.
Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

/ **2** / www.apexbt.com